The drug also showed a favorable safety profile, with minimal adverse events reported.<h4>Conclusion</h4>Reproxalap represents a first-in-class RASP inhibitor with promising efficacy and safety for the treatment of allergic conjunctivitis. Here, HHAT is linked to atopic conjunctivitis.